BioSpace News Archive

Drug Development

Rafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Rafael Pharmaceuticals, Inc. today announced the successful completion of a Phase 1b clinical trial of CPI-613 ® (devimistat) in combination with gemcitabine and cisplatin in patients with biliary tract cancer.

August 25, 2021
·
4 min read
Esoteric Testing Market on Target to Reach $66.21 Billion by 2030, at a CAGR of 12.5% Says, Allied Market Research

Rise in awareness among population for early diagnosis, and surge in number of diagnostic testing are expected to notably contribute toward the growth of the global esoteric testing market during the forecast period.

August 25, 2021
·
5 min read
Ligation Devices Market Size to Reach USD 1.68 Billion, Globally, by 2030 and Registering at CAGR 6.1% Growth Rate

The development of the ligation devices market is ascribed to mechanical progressions identified with ligation devices and expansion in flood in number surgeries, which require ligation devices for help with insignificantly intrusive methodology.

August 25, 2021
·
4 min read
TriAltus Bioscience Granted U.S. Patent for CL7 Tag Technology

TriAltus Bioscience announced that the U.S Patent and Trademark Office has issued U.S. Patent No 10,759,830 for its CLīM affinity tag system, which delivers proteins with ultra-high purity and yield in a single step.

August 25, 2021
·
2 min read
Business

Tabula Rasa and Hesperos Receive $1.9M National Institutes of Health Award for Research Focused on Preventable Drug-Induced Alzheimer’s Disease

Tabula Rasa HealthCare, Inc. and Hesperos Inc., pioneers of Human-on-a-Chip ® in vitro systems, have been awarded $1.9 million in funding from the National Institutes of Health (NIH) to investigate drug-induced dementia and develop new models that will drive Alzheimer’s research.

August 25, 2021
·
4 min read
Business

Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon Advisory Board

Dr. David Erritzoe to provide guidance on psychopharmacological research.

August 25, 2021
·
5 min read
Business

Biocom California Adds New Members to Its Board of Governors

Biocom California today announced that it has appointed Matthew Bresnahan, partner at Wilson Sonsini; Denise DeMan, founder, chair and chief executive officer of Bench International; and Thierry Diagana, Ph.D., head of the Novartis Institute for Tropical Diseases to its board of governors.

August 25, 2021
·
3 min read
Dura Substitute Market Size and Segmentation with Growth Rate Forecasts to 2028

The dura mater is the dense, leathery membrane covering and protecting the brain and spinal cord. Dural graft substitutes are used when the opening in the dura is too large to be sutured together.

August 25, 2021
·
4 min read
Pathogen Reduction System Market Global Industry Growth, Size, Share, COVID-19 Impact Analysis, Trends and Forecasts Report 2028

Pathogen reduction systems are widely used to inactivate viruses and bacteria that may contaminate blood products.

August 25, 2021
·
5 min read
Drug Development

Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), a French biotech, have announced enrollment of the first patient in the Phase 2 clinical trial of OSE-127/S95011 in Sjögren’s syndrome, with Servier sponsorship.

August 25, 2021
·
7 min read